[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"BioCheck, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":54},{"warningLetters":4,"total":53},[5,32],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":27,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":19,"reference_number":19,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},2093,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2023-05-23T13:20:00Z\">05\u002F23\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-24T04:00:00Z\">03\u002F24\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsure-biochem-laboratories-llc-646619-03242023\">Sure-Biochem Laboratories, LLC\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations I ","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tiffany Heigler\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sure-Biochem Laboratories, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1000 Atlantic Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Camden\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08104\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations I \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter #646619\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 24, 2023\u003Cbr>\n\u003Cbr>\nDear Ms. Heigler:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your contract testing laboratory, Sure-Biochem Laboratories, LLC, FEI 3023533273, at 1000 Atlantic Ave., Camden, NJ, from September 28 to October 7, 2022. Our inspection determined that you are a contract testing laboratory conducting microbial testing including, but not limited to, finished drugs.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, the drugs you tested are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your October 27, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to follow required laboratory control mechanisms and to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(a) and 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately establish and follow procedures for growth promotion testing of your microbiological media to assure suitability before use, including failing to establish appropriate challenge conditions and acceptance criteria to ensure the media could support appropriate growth. For example, your growth promotion testing conducted on July 13, 2022, for \u003Cem>Salmonella\u003C\u002Fem> media lot number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, identified light and moderate growth for the challenge organisms including \u003Cem>Escherichia coli\u003C\u002Fem>. You accepted the lot for use without noting the deviation as required by your established procedure that specifies the growth of \u003Cem>Escherichia coli\u003C\u002Fem> should be inhibited. Further, you also failed to conduct growth promotion for each lot of media received.\u003C\u002Fp>\n\n\u003Cp>Additionally, you did not validate your alternative microbial methods used to test drug products to assure the methods were equivalent to or better than USP methods. Specifically, you failed to adequately establish that your microbiological testing methods can reliably detect objectionable microorganisms. For example, Lab Numbers \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> were samples of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products marketed for pre- and post-surgical oral care and intended for use with patients who are particularly susceptible to infection.\u003C\u002Fp>\n\n\u003Cp>Your microbial method failed to detect \u003Cem>Burkholderia cepacia complex\u003C\u002Fem> (\u003Cem>Bcc\u003C\u002Fem>), and you reported “Not Detected” to your client. Subsequently, you sent microbial subcultures from these samples to another external laboratory that detected \u003Cem>Burkholderia contaminans\u003C\u002Fem> in both samples, a species that is part of \u003Cem>Bcc\u003C\u002Fem>. The ability of microbial testing methods to detect objectionable microorganisms in the presence of each drug product to be tested must be established and validated.\u003C\u002Fp>\n\n\u003Cp>In your response, you commit to performing growth promotion for every lot of purchased media and revising your growth promotion procedure to ensure media can support acceptable growth. You also acknowledge that your alternative method used to test drug products was insufficient to detect \u003Cem>Bcc\u003C\u002Fem>, and state that you will develop a procedure for the USP &lt;60&gt; test method. However, your response is inadequate because it does not address how you will review the validity of previous results using your alternative methods, or how you will communicate with your clients about these potentially noncompliant analyses. You also state that you will perform method suitability verifications for each type of product, but do not detail the actions you would take if suitability verifications are found inadequate.\u003C\u002Fp>\n\n\u003Cp>Your clients rely on your laboratory data for critical information about the quality of their drugs. Thus, it is important that your test methods are properly verified or validated, and that you use appropriate test methods to enable your clients to make proper decisions (e.g., lot disposition). Results generated using unverified or unvalidated methods can mislead customers and may put consumers at risk.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\t\u003Cli>A retrospective assessment of prior testing to assure 'suitability' of your methods for the last \u003Cstrong>(b)(4)\u003C\u002Fstrong> years of testing, and a commitment to notify customers of any deficiencies. Include any revised testing results provided to your clients with incorrect enumeration calculations.\u003C\u002Fli>\n\t\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data, records, and reporting, including results of the data review for drugs tested. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fli>\n\t\u003Cli>A procedure to establish a quantitative, acceptance criteria rather than qualitative growth entries (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) included in your growth promotion testing.\u003C\u002Fli>\n\t\u003Cli>Raw data from inoculation studies of your drugs to ensure appropriate identification of objectionable microorganisms including, but not limited to \u003Cem>Bcc\u003C\u002Fem>.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and 211.22(d)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) lacked adequate control over your testing operations and failed to ensure that you had suitable procedures. For example, your QU failed:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>To adequately retain documentation for the review, approval, or rejection, of laboratory testing materials such as buffers, reagents, and media. There is a lack of assurance that testing materials used to conduct microbial testing meet all appropriate specifications before use of an incoming lot, and include evaluation of certificates of analysis (COA).\u003C\u002Fli>\n\t\u003Cli>To ensure procedures were followed to document and retain records such as laboratory investigations, corrective action and preventive action plans (CAPA), and change controls. You told our investigators that you were not following a number of your standard operating procedures (SOPs).\u003C\u002Fli>\n\t\u003Cli>To establish an adequate CGMP training program. You lacked appropriate resources to perform QU related functions and our inspection revealed basic CGMP violations.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response, you admit to not adhering to your SOPs and state that you will document receipt of all incoming testing materials and retain the associated documentation. You also committed to hiring a quality consultant to develop a CGMP training program and perform quality functions. However, your response is inadequate because you did not commit to conducting a retrospective review to ensure materials used for drug product testing were suitable for their intended use. In addition, you state that your lab technician will attend “21 CFR 820 training,” which is applicable to medical devices, but does not address the lack of CGMP training for drugs.\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM070337.pdf .\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A retrospective review of records for testing using received materials to assure correct materials were used and acceptable.\u003C\u002Fli>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each lot and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your QU. Your change management program should also include provisions for determining change effectiveness.\u003C\u002Fli>\n\t\u003Cli>An independent summary of your retrospective review of records for \u003Cstrong>(b)(4)\u003C\u002Fstrong> years of testing using received materials to assure correct materials were used and acceptable.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your laboratory records do not include complete testing data to support the analysis performed. For example, your records lack a statement of methods used for testing, a statement of the results of tests and how they compare to the established specifications, a record of all critical equipment used, and confirmation of compliance with testing conditions. Furthermore, you were unable to provide raw data to support the suitability of your alternative methods for each drug tested.\u003C\u002Fp>\n\n\u003Cp>All CGMP-related data must be retained by all laboratories, including contract testing laboratories, to enable appropriate assessments and decisions by the QU and customers, and to demonstrate ongoing control.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you will revise your records to include the missing information. Your response is inadequate because you make no commitment to retrospectively review prior testing for completeness, validity, or for errors.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive independent assessment of documentation practices used throughout your laboratory operations to determine where documentation is insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\n\t\u003Cli>An independent assessment that summarizes the potential impact on product quality of the inadequate documentation.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Responsibilities of a Contract Testing Lab\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your clients. It is essential that you understand your responsibility to operate in full compliance with CGMP when performing analytical work for your customers. Your laboratory role is critical to the pharmaceutical supply chain, and it is essential that you meet all CGMPs related to your function. As part of this responsibility, it is essential that you provide prompt, complete, and transparent analytical information to your customers (e.g., manufacturers) to enable them to handle their quality responsibilities related to batch evaluation and contractor oversight. This responsibility includes, but is not limited to, conveying to the customer any out-of-specification (OOS) investigations performed by your firm.\u003C\u002Fp>\n\n\u003Cp>For additional information refer to \u003Cem>FDA Guidance for Industry Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> (https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant (i.e., an independent third party) qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you test. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003Cbr>\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please send your electronic reply to Yvette Johnson, Compliance Officer, at Yvette.Johnson@fda.hhs.gov and ORAPHARM1_RESPONSES@fda.hhs.gov. Identify your response with FEI# 3023533273.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lisa Harlan\u003Cbr>\nProgram Division Director\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nOffice of Pharmaceutical Quality Operations\u003Cbr>\nDivision I\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nTiffany Heigler\n\nRecipient Title\n\nPresident and CEO\n\nSure-Biochem Laboratories, LLC\n\n1000 Atlantic Ave\n\nCamden, NJ 08104\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWarning Letter #646619\n\nMarch 24, 2023\n\nDear Ms. Heigler:\n\nThe U.S. Food and Drug Administration (FDA) inspected your contract testing laboratory, Sure-Biochem Laboratories, LLC, FEI 3023533273, at 1000 Atlantic Ave., Camden, NJ, from September 28 to October 7, 2022. Our inspection determined that you are a contract testing laboratory conducting microbial testing including, but not limited to, finished drugs.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, the drugs you tested are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your October 27, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to follow required laboratory control mechanisms and to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(a) and 211.160(b)).\n\nYou failed to adequately establish and follow procedures for growth promotion testing of your microbiological media to assure suitability before use, including failing to establish appropriate challenge conditions and acceptance criteria to ensure the media could support appropriate growth. For example, your growth promotion testing conducted on July 13, 2022, for Salmonella media lot number (b)(4), identified light and moderate growth for the challenge organisms including Escherichia coli. You accepted the lot for use without noting the deviation as required by your established procedure that specifies the growth of Escherichia coli should be inhibited. Further, you also failed to conduct growth promotion for each lot of media received.\n\nAdditionally, you did not validate your alternative microbial methods used to test drug products to assure the methods were equivalent to or better than USP methods. Specifically, you failed to adequately establish that your microbiological testing methods can reliably detect objectionable microorganisms. For example, Lab Numbers (b)(4) and (b)(4) were samples of (b)(4) drug products marketed for pre- and post-surgical oral care and intended for use with patients who are particularly susceptible to infection.\n\nYour microbial method failed to detect Burkholderia cepacia complex (Bcc), and you reported “Not Detected” to your client. Subsequently, you sent microbial subcultures from these samples to another external laboratory that detected Burkholderia contaminans in both samples, a species that is part of Bcc. The ability of microbial testing methods to detect objectionable microorganisms in the presence of each drug product to be tested must be established and validated.\n\nIn your response, you commit to performing growth promotion for every lot of purchased media and revising your growth promotion procedure to ensure media can support acceptable growth. You also acknowledge that your alternative method used to test drug products was insufficient to detect Bcc, and state that you will develop a procedure for the USP \u003C60> test method. However, your response is inadequate because it does not address how you will review the validity of previous results using your alternative methods, or how you will communicate with your clients about these potentially noncompliant analyses. You also state that you will perform method suitability verifications for each type of product, but do not detail the actions you would take if suitability verifications are found inadequate.\n\nYour clients rely on your laboratory data for critical information about the quality of their drugs. Thus, it is important that your test methods are properly verified or validated, and that you use appropriate test methods to enable your clients to make proper decisions (e.g., lot disposition). Results generated using unverified or unvalidated methods can mislead customers and may put consumers at risk.\n\nIn response to this letter, provide:\n\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\nA retrospective assessment of prior testing to assure 'suitability' of your methods for the last (b)(4) years of testing, and a commitment to notify customers of any deficiencies. Include any revised testing results provided to your clients with incorrect enumeration calculations.\n\nA comprehensive investigation into the extent of the inaccuracies in data, records, and reporting, including results of the data review for drugs tested. Include a detailed description of the scope and root causes of your data integrity lapses.\n\nA procedure to establish a quantitative, acceptance criteria rather than qualitative growth entries (e.g., (b)(4)) included in your growth promotion testing.\n\nRaw data from inoculation studies of your drugs to ensure appropriate identification of objectionable microorganisms including, but not limited to Bcc.\n\n2. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and 211.22(d)).\n\nYour quality unit (QU) lacked adequate control over your testing operations and failed to ensure that you had suitable procedures. For example, your QU failed:\n\nTo adequately retain documentation for the review, approval, or rejection, of laboratory testing materials such as buffers, reagents, and media. There is a lack of assurance that testing materials used to conduct microbial testing meet all appropriate specifications before use of an incoming lot, and include evaluation of certificates of analysis (COA).\n\nTo ensure procedures were followed to document and retain records such as laboratory investigations, corrective action and preventive action plans (CAPA), and change controls. You told our investigators that you were not following a number of your standard operating procedures (SOPs).\n\nTo establish an adequate CGMP training program. You lacked appropriate resources to perform QU related functions and our inspection revealed basic CGMP violations.\n\nIn your response, you admit to not adhering to your SOPs and state that you will document receipt of all incoming testing materials and retain the associated documentation. You also committed to hiring a quality consultant to develop a CGMP training program and perform quality functions. However, your response is inadequate because you did not commit to conducting a retrospective review to ensure materials used for drug product testing were suitable for their intended use. In addition, you state that your lab technician will attend “21 CFR 820 training,” which is applicable to medical devices, but does not address the lack of CGMP training for drugs.\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM070337.pdf .\n\nIn response to this letter, provide:\n\nA retrospective review of records for testing using received materials to assure correct materials were used and acceptable.\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each lot and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nA comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your QU. Your change management program should also include provisions for determining change effectiveness.\n\nAn independent summary of your retrospective review of records for (b)(4) years of testing using received materials to assure correct materials were used and acceptable.\n\n3. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\n\nYour laboratory records do not include complete testing data to support the analysis performed. For example, your records lack a statement of methods used for testing, a statement of the results of tests and how they compare to the established specifications, a record of all critical equipment used, and confirmation of compliance with testing conditions. Furthermore, you were unable to provide raw data to support the suitability of your alternative methods for each drug tested.\n\nAll CGMP-related data must be retained by all laboratories, including contract testing laboratories, to enable appropriate assessments and decisions by the QU and customers, and to demonstrate ongoing control.\n\nIn your response, you state that you will revise your records to include the missing information. Your response is inadequate because you make no commitment to retrospectively review prior testing for completeness, validity, or for errors.\n\nIn response to this letter, provide:\n\nA comprehensive independent assessment of documentation practices used throughout your laboratory operations to determine where documentation is insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nAn independent assessment that summarizes the potential impact on product quality of the inadequate documentation.\n\nResponsibilities of a Contract Testing Lab\n\nFDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your clients. It is essential that you understand your responsibility to operate in full compliance with CGMP when performing analytical work for your customers. Your laboratory role is critical to the pharmaceutical supply chain, and it is essential that you meet all CGMPs related to your function. As part of this responsibility, it is essential that you provide prompt, complete, and transparent analytical information to your customers (e.g., manufacturers) to enable them to handle their quality responsibilities related to batch evaluation and contractor oversight. This responsibility includes, but is not limited to, conveying to the customer any out-of-specification (OOS) investigations performed by your firm.\n\nFor additional information refer to FDA Guidance for Industry Contract Manufacturing Arrangements for Drugs: Quality Agreements (https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant (i.e., an independent third party) qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you test. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease send your electronic reply to Yvette Johnson, Compliance Officer, at Yvette.Johnson@fda.hhs.gov and ORAPHARM1_RESPONSES@fda.hhs.gov. Identify your response with FEI# 3023533273.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\n\nU.S. Food and Drug Administration\n\nOffice of Pharmaceutical Quality Operations\n\nDivision I","Sure-Biochem Laboratories, LLC","sure-biochem-laboratories-llc-646619-03242023","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsure-biochem-laboratories-llc-646619-03242023","2026-10-26T08:10:08.213568+00:00","Warning Letter","Issued","2023-05-23","646619","Drugs","Division of Pharmaceutical Quality Operations I","Tiffany Heigler","2026-08-20T01:06:32.524+00:00","Via Email","2023-03-24",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":26,"closeout_date":19,"issuing_office":38,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},2700,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2022-05-03T13:20:00Z\">05\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-04-20T04:00:00Z\">04\u002F20\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmiami-university-department-chemistry-and-biochemistry-623494-04202022\">Miami University Department of Chemistry and Biochemistry\u003C\u002Fa>","Pharmaceutical Quality Operations Division III","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. David L. Tierney\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Principal Investigator\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Miami University Department of Chemistry and Biochemistry\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>651 East High Street, Room 160\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Oxford\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>45056\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Pharmaceutical Quality Operations Division III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 20, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCase # 623494\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Tierney:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your contract testing laboratory, at Miami University, FEI 3009095423, at 651 East High Street, Oxford, from November 1 to November 5, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your November 29, 2021, response to our Form FDA 483 in detail. We note that when the inspection was initiated, on November 1, 2021, Dr. Richard T. Taylor was the most responsible person onsite. However, during the inspection Dr. Taylor stated that he was no longer in the same role as on the first day of the inspection. Dr. David L. Tierney then stated that he became responsible for the testing performed by the laboratory only as of November 1, 2021.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific deviations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to exercise sufficient controls over computerized systems to prevent unauthorized access or changes to data, and failure to have adequate controls to prevent omission of data.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to implement adequate controls to ensure the integrity of data generated at your facility. Your firm is a contract testing laboratory that performs CGMP testing of crude heparin and active pharmaceutical ingredient (API) heparin sodium, USP. Testing performed by your firm, among other things, includes elemental impurity testing via \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;and identity testing via \u003Cstrong>(b)(4)\u003C\u002Fstrong>. \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing of heparin includes analyzing samples for the presence of the contaminant Over-sulfated Chondroitin Sulfate (OSCS), of which historical contamination of heparin has been linked with adverse events, including death.\u003C\u002Fp>\n\n\u003Cp>Immediately before the initiation of the FDA’s inspection, your firm, and the representatives from your heparin sodium, USP, customer, performed an audit. After reviewing the raw \u003Cstrong>(b)(4)\u003C\u002Fstrong> test data, your customer’s risk assessment determined that one of your student analysts had “falsified” data. Representatives from your firm, and from your customer, informed FDA investigators that this was the first time the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw data was reviewed since you initiated CGMP testing at your firm. The falsification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> data occurred from approximately 2018 to 2021 and consisted of an analyst entering arbitrary values for sample, spike, and correlation.\u003C\u002Fp>\n\n\u003Cp>Furthermore, in addition to concerns about data falsification, additional data integrity concerns were identified, which include the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>All \u003Cstrong>(b)(4)\u003C\u002Fstrong> sample results were stored in an uncontrolled folder that could be manipulated by any user.\u003C\u002Fli>\n\t\u003Cli>The \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment were used by numerous people at the University, including faculty members and graduate students. All users shared one master login for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> which allowed for full administrative access.\u003C\u002Fli>\n\t\u003Cli>The \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw data was not backed-up since CGMP testing began.\u003C\u002Fli>\n\t\u003Cli>The software that runs the \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not have an audit trail.\u003C\u002Fli>\n\t\u003Cli>The Excel spreadsheet used to calculate spike recovery and final results for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> analysis was uncontrolled.\u003C\u002Fli>\n\t\u003Cli>The software that runs the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment was not validated.\u003C\u002Fli>\n\t\u003Cli>Sample reprocessing was not formally documented, although your firm stated reprocessing did occur.\u003C\u002Fli>\n\t\u003Cli>In \u003Cstrong>(b)(4)\u003C\u002Fstrong> analyses, peaks of interest in the spectrum were chosen \u003Cstrong>(b)(4)\u003C\u002Fstrong> and were not covered by an established procedure.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response, you stated that the “data manipulation” was associated with a single analyst whose “motivation was exclusively to avoid the reanalysis of samples that did not pass system suitability requirements.” You also stated that the “data manipulation” was not performed to create results that conform to specification where they otherwise did not. However, we do not agree with your conclusion. All the elements identified in the risk exposure assessment for heparin are required to be quantified conclusively, in accordance with USP. A lack of conclusive, quantitative data for any of the elements reported indicates that the product has not been adequately analyzed for pharmaceutical quality. These system suitability failures, among other deficiencies, demonstrate that the results are not reliable, reportable, or suitable to support the quality of heparin drug or drug products. Therefore, you cannot conclude that the results generated were within, or failing, specification.\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you analyze for your customers. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdata-integrity-and-compliance-drug-cgmp-questions-and-answers-guidance-industry\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdata-integrity-and-compliance-drug-cgmp-questions-and-answers-guidance-industry\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>A. A comprehensive investigation into the extent of the inaccuracies in data records and reporting which should include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>(1) A detailed investigation protocol and methodology; (2) a summary of all systems to be covered by the assessment; (3) a justification for any part of your operation that you propose to exclude.\u003C\u002Fli>\n\t\u003Cli>Interviews of current and former employees to identify the nature, scope, and the root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003C\u002Fli>\n\t\u003Cli>An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003C\u002Fli>\n\t\u003Cli>A comprehensive retrospective evaluation of the nature of the testing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>B. A current risk assessment of the potential effects of the observed failures on the quality of the drugs you tested. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fp>\n\n\u003Cp>C. A management strategy for your firm that includes the details of your global corrective action and preventive action (CAPA) plan. Your strategy should include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, and all data submitted to FDA.\u003C\u002Fli>\n\t\u003Cli>A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003C\u002Fli>\n\t\u003Cli>Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of the drugs you tested, such as notifying your customers, conducting additional testing, and enhanced complaint monitoring.\u003C\u002Fli>\n\t\u003Cli>Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003C\u002Fli>\n\t\u003Cli>A status report for any of the above activities already underway or completed.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A complete assessment of documentation systems used throughout your laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>For further reference regarding heparin, see the guidance for industry \u003Cem>Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Quality\u003C\u002Fem> available online at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM291390.pdf\">http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM291390.pdf\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure of your quality unit to ensure that drugs are appropriately tested and the results are reported.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm did not have an adequate quality unit (QU) or quality system in place to provide appropriate oversight of laboratory operations. Prior to communication from FDA asking if your firm was ready for FDA inspection, your firm did not have procedures in place and did not have an established QU to provide oversight over the CGMP testing performed by your firm. Additionally, during the course of the inspection, FDA investigators were informed that the Principal Investigator, who is the most responsible person at the firm, was changed on the first day of the FDA’s inspection. The previous Principal Investigator is now a consultant for the firm.\u003C\u002Fp>\n\n\u003Cp>Without an adequate QU and quality system in place, there is inadequate assurance that controls are implemented to ensure that your CGMP testing operations are performing in a state of control.\u003C\u002Fp>\n\n\u003Cp>It appears your firm attempted to create a quality system, and corresponding procedures, in a very short timeframe to comply with applicable requirements, after communication from FDA asking if your firm was ready for FDA inspection. In your response, and during our inspection, you provided over twenty recently created procedures including: Policy for CAPA, Root Cause Analysis, and Quality System Manual. However, all these procedures were created after the FDA initially contacted your firm, but also after you had provided test results used for CGMP purposes including release of drugs into interstate commerce. Although various procedures were provided during the inspection and in your firm’s response, these procedures appear to lack sufficient detail to be effective. Additionally, you did not provide evidence to demonstrate that your firm adequately implemented and follows the procedures.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include:\u003Cbr>\n&nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to ensure training is regularly conducted by qualified individuals and covers, at a minimum, the particular operations that each employee performs and CGMP as they relate to the employee’s functions.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to ensure that laboratory personnel who performed CGMP testing were adequately trained in current good manufacturing practice requirements. CGMP testing is performed by both faculty members and graduate students at your facility. Your firm lacked the adequate documentation to demonstrate that laboratory personnel were adequately trained in their respective job functions.\u003C\u002Fp>\n\n\u003Cp>In your response, and during our inspection, you provided training procedures entitled “Good Manufacturing Practices &amp; Training” and “Employee Training,” both created approximately a week before the initiation of our pre-announced inspection. Your response is inadequate as your firm began CGMP testing prior to the generation of your procedures, and you failed to perform a retrospective assessment of previous laboratory personnel to demonstrate that they had the expertise or training to support the test results provided to your customers.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fp>\n\n\u003Cp>• A retrospective assessment of previous laboratory personnel to demonstrate that they had the expertise to properly perform CGMP testing. The timeframe of this assessment should ensure that it includes CGMP testing of all drugs within expiry.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the deviations we identified at your firm, we strongly recommend engaging a consultant qualified to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>API Testing Ceased\u002FSuspended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to cease trace metal analyses and suspend \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing operations of APIs at this facility. In response to this letter, clarify whether you intend to resume testing any drugs at this facility in the future.\u003C\u002Fp>\n\n\u003Cp>If you plan to resume any CGMP testing, notify this office before resuming your operations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\n\n\u003Cp>Correct any deviations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved deviations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any deviations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Tina M. Pawlowski, Compliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter above (WL #623494). If you have questions regarding the contents of this letter, please contact Tina M. Pawlowski at (313) 393-8217.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Nicholas Lyons\u003Cbr>\nActing Program Division Director\u003Cbr>\nPharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\u003Cp>Cc:\u003Cbr>\nCourtney E. Stanton\u003Cbr>\nPresident\u003Cbr>\nSmithfield Bioscience Inc.\u003Cbr>\n12150 Best Place\u003Cbr>\nCincinnati, Ohio 45241-1569\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDr. David L. Tierney\n\nRecipient Title\n\nPrincipal Investigator\n\nMiami University Department of Chemistry and Biochemistry\n\n651 East High Street, Room 160\n\nOxford, OH 45056\n\nUnited States\n\nIssuing Office:\n\nPharmaceutical Quality Operations Division III\n\nUnited States\n\nApril 20, 2022\n\nWARNING LETTER\n\nCase # 623494\n\nDear Dr. Tierney:\n\nThe U.S. Food and Drug Administration (FDA) inspected your contract testing laboratory, at Miami University, FEI 3009095423, at 651 East High Street, Oxford, from November 1 to November 5, 2021.\n\nThis warning letter summarizes significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your November 29, 2021, response to our Form FDA 483 in detail. We note that when the inspection was initiated, on November 1, 2021, Dr. Richard T. Taylor was the most responsible person onsite. However, during the inspection Dr. Taylor stated that he was no longer in the same role as on the first day of the inspection. Dr. David L. Tierney then stated that he became responsible for the testing performed by the laboratory only as of November 1, 2021.\n\nDuring our inspection, our investigators observed specific deviations including, but not limited to, the following.\n\n1. Failure to exercise sufficient controls over computerized systems to prevent unauthorized access or changes to data, and failure to have adequate controls to prevent omission of data.\n\nYour firm failed to implement adequate controls to ensure the integrity of data generated at your facility. Your firm is a contract testing laboratory that performs CGMP testing of crude heparin and active pharmaceutical ingredient (API) heparin sodium, USP. Testing performed by your firm, among other things, includes elemental impurity testing via (b)(4) and identity testing via (b)(4). (b)(4) testing of heparin includes analyzing samples for the presence of the contaminant Over-sulfated Chondroitin Sulfate (OSCS), of which historical contamination of heparin has been linked with adverse events, including death.\n\nImmediately before the initiation of the FDA’s inspection, your firm, and the representatives from your heparin sodium, USP, customer, performed an audit. After reviewing the raw (b)(4) test data, your customer’s risk assessment determined that one of your student analysts had “falsified” data. Representatives from your firm, and from your customer, informed FDA investigators that this was the first time the (b)(4) and (b)(4) raw data was reviewed since you initiated CGMP testing at your firm. The falsification of (b)(4) data occurred from approximately 2018 to 2021 and consisted of an analyst entering arbitrary values for sample, spike, and correlation.\n\nFurthermore, in addition to concerns about data falsification, additional data integrity concerns were identified, which include the following:\n\nAll (b)(4) sample results were stored in an uncontrolled folder that could be manipulated by any user.\n\nThe (b)(4) and (b)(4) equipment were used by numerous people at the University, including faculty members and graduate students. All users shared one master login for the (b)(4) which allowed for full administrative access.\n\nThe (b)(4) raw data was not backed-up since CGMP testing began.\n\nThe software that runs the (b)(4) did not have an audit trail.\n\nThe Excel spreadsheet used to calculate spike recovery and final results for the (b)(4) analysis was uncontrolled.\n\nThe software that runs the (b)(4) and (b)(4) equipment was not validated.\n\nSample reprocessing was not formally documented, although your firm stated reprocessing did occur.\n\nIn (b)(4) analyses, peaks of interest in the spectrum were chosen (b)(4) and were not covered by an established procedure.\n\nIn your response, you stated that the “data manipulation” was associated with a single analyst whose “motivation was exclusively to avoid the reanalysis of samples that did not pass system suitability requirements.” You also stated that the “data manipulation” was not performed to create results that conform to specification where they otherwise did not. However, we do not agree with your conclusion. All the elements identified in the risk exposure assessment for heparin are required to be quantified conclusively, in accordance with USP. A lack of conclusive, quantitative data for any of the elements reported indicates that the product has not been adequately analyzed for pharmaceutical quality. These system suitability failures, among other deficiencies, demonstrate that the results are not reliable, reportable, or suitable to support the quality of heparin drug or drug products. Therefore, you cannot conclude that the results generated were within, or failing, specification.\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you analyze for your customers. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdata-integrity-and-compliance-drug-cgmp-questions-and-answers-guidance-industry.\n\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide the following:\n\nA. A comprehensive investigation into the extent of the inaccuracies in data records and reporting which should include:\n\n(1) A detailed investigation protocol and methodology; (2) a summary of all systems to be covered by the assessment; (3) a justification for any part of your operation that you propose to exclude.\n\nInterviews of current and former employees to identify the nature, scope, and the root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\n\nAn assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\n\nA comprehensive retrospective evaluation of the nature of the testing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\n\nB. A current risk assessment of the potential effects of the observed failures on the quality of the drugs you tested. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\nC. A management strategy for your firm that includes the details of your global corrective action and preventive action (CAPA) plan. Your strategy should include:\n\nA detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, and all data submitted to FDA.\n\nA comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\n\nInterim measures describing the actions you have taken or will take to protect patients and to ensure the quality of the drugs you tested, such as notifying your customers, conducting additional testing, and enhanced complaint monitoring.\n\nLong-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\n\nA status report for any of the above activities already underway or completed.\n\nAdditionally, provide the following:\n\nA complete assessment of documentation systems used throughout your laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nFor further reference regarding heparin, see the guidance for industry Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Quality available online at http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM291390.pdf.\n\n2. Failure of your quality unit to ensure that drugs are appropriately tested and the results are reported.\n\nYour firm did not have an adequate quality unit (QU) or quality system in place to provide appropriate oversight of laboratory operations. Prior to communication from FDA asking if your firm was ready for FDA inspection, your firm did not have procedures in place and did not have an established QU to provide oversight over the CGMP testing performed by your firm. Additionally, during the course of the inspection, FDA investigators were informed that the Principal Investigator, who is the most responsible person at the firm, was changed on the first day of the FDA’s inspection. The previous Principal Investigator is now a consultant for the firm.\n\nWithout an adequate QU and quality system in place, there is inadequate assurance that controls are implemented to ensure that your CGMP testing operations are performing in a state of control.\n\nIt appears your firm attempted to create a quality system, and corresponding procedures, in a very short timeframe to comply with applicable requirements, after communication from FDA asking if your firm was ready for FDA inspection. In your response, and during our inspection, you provided over twenty recently created procedures including: Policy for CAPA, Root Cause Analysis, and Quality System Manual. However, all these procedures were created after the FDA initially contacted your firm, but also after you had provided test results used for CGMP purposes including release of drugs into interstate commerce. Although various procedures were provided during the inspection and in your firm’s response, these procedures appear to lack sufficient detail to be effective. Additionally, you did not provide evidence to demonstrate that your firm adequately implemented and follows the procedures.\n\nIn response to this letter, provide the following:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\n3. Failure to ensure training is regularly conducted by qualified individuals and covers, at a minimum, the particular operations that each employee performs and CGMP as they relate to the employee’s functions.\n\nYou failed to ensure that laboratory personnel who performed CGMP testing were adequately trained in current good manufacturing practice requirements. CGMP testing is performed by both faculty members and graduate students at your facility. Your firm lacked the adequate documentation to demonstrate that laboratory personnel were adequately trained in their respective job functions.\n\nIn your response, and during our inspection, you provided training procedures entitled “Good Manufacturing Practices & Training” and “Employee Training,” both created approximately a week before the initiation of our pre-announced inspection. Your response is inadequate as your firm began CGMP testing prior to the generation of your procedures, and you failed to perform a retrospective assessment of previous laboratory personnel to demonstrate that they had the expertise or training to support the test results provided to your customers.\n\nIn response to this letter, provide the following:\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• A retrospective assessment of previous laboratory personnel to demonstrate that they had the expertise to properly perform CGMP testing. The timeframe of this assessment should ensure that it includes CGMP testing of all drugs within expiry.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the deviations we identified at your firm, we strongly recommend engaging a consultant qualified to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nAPI Testing Ceased\u002FSuspended\n\nWe acknowledge your commitment to cease trace metal analyses and suspend (b)(4) testing operations of APIs at this facility. In response to this letter, clarify whether you intend to resume testing any drugs at this facility in the future.\n\nIf you plan to resume any CGMP testing, notify this office before resuming your operations.\n\nConclusion\n\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\n\nCorrect any deviations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved deviations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any deviations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Tina M. Pawlowski, Compliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations III\n\nYour written notification should refer to the Warning Letter above (WL #623494). If you have questions regarding the contents of this letter, please contact Tina M. Pawlowski at (313) 393-8217.\n\nSincerely,\n\n\u002FS\u002F\n\nNicholas Lyons\n\nActing Program Division Director\n\nPharmaceutical Quality Operations Division III\n\nCc:\n\nCourtney E. Stanton\n\nPresident\n\nSmithfield Bioscience Inc.\n\n12150 Best Place\n\nCincinnati, Ohio 45241-1569","Miami University Department of Chemistry and Biochemistry","miami-university-department-chemistry-and-biochemistry-623494-04202022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmiami-university-department-chemistry-and-biochemistry-623494-04202022","2026-10-26T08:09:24.613486+00:00","2022-05-03","623494","Dr. David L. Tierney","2026-08-20T01:57:36.41+00:00","VIA UPS","2022-04-20",2,{"510k":55,"classification":56,"enforcement":57,"event":58,"event_backfill":59,"pma":60,"warning_letter":61},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]